Healthcare provider profile · identity verified

Cierra Jade Relyea, FNP

Nurse Practitioner · HAYMARKET, VA · NPI 1669083416

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	357	55
Levothyroxine Sodium	Levothyroxine Sodium	263	39
Escitalopram Oxalate	Escitalopram Oxalate	249	29
Gabapentin	Gabapentin	223	35
Amlodipine Besylate	Amlodipine Besylate	221	33
Trazodone Hcl	Trazodone Hcl	205	30
Furosemide	Furosemide	196	37
Metoprolol Succinate	Metoprolol Succinate	182	32
Potassium Chloride	Potassium Chloride	179	32
Pantoprazole Sodium	Pantoprazole Sodium	160	28
Donepezil Hcl	Donepezil Hcl	150	18
Sertraline Hcl	Sertraline Hcl	139	24
Omeprazole	Omeprazole	135	21
Losartan Potassium	Losartan Potassium	133	24
Eliquis	Apixaban	132	23
Carvedilol	Carvedilol	122	17
Mirtazapine	Mirtazapine	122	20
Lisinopril	Lisinopril	117	24
Memantine Hcl	Memantine Hcl	112	15
Tamsulosin Hcl	Tamsulosin Hcl	109	21
Quetiapine Fumarate	Quetiapine Fumarate	98	20
Tramadol Hcl	Tramadol Hcl	95	23
Buspirone Hcl	Buspirone Hcl	90	11
Aripiprazole	Aripiprazole	76	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	73	15
Simvastatin	Simvastatin	73	11
Duloxetine Hcl	Duloxetine Hcl	71	11
Rosuvastatin Calcium	Rosuvastatin Calcium	69	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	68	12
Lorazepam	Lorazepam	64	22
Metformin Hcl	Metformin Hcl	64	12
Bumetanide	Bumetanide	63	suppressed
Spironolactone	Spironolactone	57	suppressed
Famotidine	Famotidine	56	suppressed
Hydralazine Hcl	Hydralazine Hcl	51	12
Methenamine Hippurate	Methenamine Hippurate	49	suppressed
Montelukast Sodium	Montelukast Sodium	47	suppressed
Fluticasone Propionate	Fluticasone Propionate	44	20
Divalproex Sodium	Divalproex Sodium	43	suppressed
Xarelto	Rivaroxaban	42	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	41	28
Myrbetriq	Mirabegron	40	suppressed
Clopidogrel	Clopidogrel Bisulfate	39	suppressed
Valsartan	Valsartan	38	suppressed
Latanoprost	Latanoprost	37	suppressed
Jardiance	Empagliflozin	36	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	35	27
Ondansetron Hcl	Ondansetron Hcl	35	28
Bupropion Xl	Bupropion Hcl	34	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	32	20
Dicyclomine Hcl	Dicyclomine Hcl	31	suppressed
Memantine Hcl Er	Memantine Hcl	31	suppressed
Diclofenac Sodium	Diclofenac Sodium	29	17
Oxybutynin Chloride	Oxybutynin Chloride	28	suppressed
Pregabalin	Pregabalin	28	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Hydrocortisone	Hydrocortisone	25	13
Nystatin	Nystatin	25	12
Alprazolam	Alprazolam	24	suppressed
Ipratropium Bromide	Ipratropium Bromide	24	suppressed
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Prednisone	Prednisone	24	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	23	15
Cephalexin	Cephalexin	23	16
Oxybutynin Chloride Er	Oxybutynin Chloride	23	suppressed
Alendronate Sodium	Alendronate Sodium	22	suppressed
Loperamide	Loperamide Hcl	22	17
Midodrine Hcl	Midodrine Hcl	22	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Torsemide	Torsemide	20	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	19	suppressed
Clotrimazole	Clotrimazole	19	suppressed
Enalapril Maleate	Enalapril Maleate	19	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Metformin Hcl Er	Metformin Hcl	19	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Ozempic	Semaglutide	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Timolol Maleate	Timolol Maleate	18	suppressed
Azithromycin	Azithromycin	17	14
Ketoconazole	Ketoconazole	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	11
Benazepril Hcl	Benazepril Hcl	16	suppressed
Clonazepam	Clonazepam	16	suppressed
Entresto	Sacubitril/Valsartan	16	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	15	suppressed
Lumigan	Bimatoprost	15	suppressed
Atenolol	Atenolol	14	suppressed
Cefuroxime	Cefuroxime Axetil	14	suppressed
Telmisartan	Telmisartan	14	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	13	suppressed
Lubiprostone	Lubiprostone	13	suppressed
Metolazone	Metolazone	13	suppressed
Pramipexole Er	Pramipexole Di-Hcl	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Folic Acid	Folic Acid	12	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Gemtesa	Vibegron	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error